对比海星医疗(纳斯达克：重症监护病房)和艾比埃德(纳斯达克：aBMD)

SeaStar Medical (NASDAQ:ICU – Get Rating) and Abiomed (NASDAQ:ABMD – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Valuation and Earnings

This table compares SeaStar Medical and Abiomed's revenue, earnings per share (EPS) and valuation.

Get SeaStar Medical alerts:

Abiomed has higher revenue and earnings than SeaStar Medical.

Risk & Volatility

SeaStar Medical has a beta of -0.45, indicating that its stock price is 145% less volatile than the S&P 500. Comparatively, Abiomed has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.

Insider & Institutional Ownership

94.5% of Abiomed shares are owned by institutional investors. 2.5% of Abiomed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares SeaStar Medical and Abiomed's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and price targets for SeaStar Medical and Abiomed, as provided by MarketBeat.

Abiomed has a consensus price target of $350.50, indicating a potential downside of 8.01%. Given Abiomed's higher possible upside, analysts clearly believe Abiomed is more favorable than SeaStar Medical.

Summary

Abiomed beats SeaStar Medical on 10 of the 10 factors compared between the two stocks.

About SeaStar Medical

(Get Rating)

SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.

About Abiomed

(Get Rating)

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Receive News & Ratings for SeaStar Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaStar Medical and related companies with MarketBeat.com's FREE daily email newsletter.